[AML(M7) associated with t(16;21)(p11;q22) showing relapse after unrelated bone marrow transplantation and disappearance of TLS/FUS-ERG mRNA].

Abstract

A 3-year-old boy with poorly prognostic acute megakaryoblastic leukemia (AML M7) showing t(16;21)(p11;q22) karyotype underwent unrelated bone marrow transplantation (U-BMT) during his first hematological remission. The conditioning regimen consisted of BU, VP-16 and L-PAM. Engraftment was smooth, but the patient developed grade I acute GVHD. During hematological remission before U-BMT, the TLS/FUS-ERG chimeric transcript of t(16;21)(p11;q22) was consistently detectable as minimal residual disease (MRD) by RT-PCR. However, after U-BMT it soon became undetectable. There was no detectable MRD until 7 months after U-BMT, but bone marrow relapse occurred 10 months after U-BMT. We consider that U-BMT is a promising treatment for t(16;21)(p11;q22) AML. However, an intensified conditioning regimen or modification of GVHD prophylaxis is needed.

• Authors: Y Fukushima, N Fujii, Y Tabata, Y Nishimura, T Fusaoka, T Yoshihara, K Tsunamoto, Y Kasubuchi, A Morimoto, S Hibi, K Taketani, Y Hayashi, S Imashuku
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 42 Issue 6 Pg. 502-6 (Jun 2001) ISSN: 0485-1439 [Print] Japan
• PMID: 11505530 (Publication Type: Case Reports, English Abstract, Journal Article, Review)

Chemical References

• Oncogene Proteins, Fusion
• RNA, Messenger
• RNA-Binding Protein FUS
• TLS-ERG fusion protein, human

Topics

• Bone Marrow Transplantation
• Child, Preschool
• Chromosomes, Human, Pair 16
• Chromosomes, Human, Pair 21
• Humans
• Leukemia, Megakaryoblastic, Acute (genetics, therapy)
• Male
• Oncogene Proteins, Fusion (genetics)
• RNA, Messenger (analysis)
• RNA-Binding Protein FUS
• Recurrence
• Translocation, Genetic